CROI 2012: HIV/HCV co-infected people see improved HCV cure rates with Victrelis

Posted on March 26, 2012 by admin

Source-Project Inform

Results from a small study of 100 co-infected people treated with Victrelis + pegylated interferon + ribavirin showed that 61% had undetectable viral loads at 12 weeks after stopping their hepatitis C treatment.

All study participants were given pegylated interferon + ribavirin for the first 4 weeks of treatment. About 2/3 had Victrelis added to their regimen for the next 44 weeks while the other third continued on pegylated interferon + ribavirin alone. Nearly all participants were on a boosted protease inhibitor HIV regimen.
The average age of the participants was 44, and 31% were women. Most people had high HCV viral loads, while 5% had cirrhosis. Nearly 65% had HCV genotype 1a while the others had 1b. CD4 counts averaged 580 and all had undetectable HIV viral load.

The following chart describes 12-week post-treatment undetectable HCV viral loads (B/PR = Victrelis + pegylated interferon + ribavirin):

Undetectable HCV	B/PR	PR
4 wks	4.7%	8.8%
8 wks	37.5%	14.7%
12 wks	56.5%	25.0%
24 wks	70.5%	34.4%
48 wks	65.6%	29.4%
12 wks post	60.7%	26.5%

The following details should be noted about this study:

• Two people saw their HCV return after being undetectable at week 48.
• HIV viral loads became detectable in 3 people taking Victrelis.
• CD4 counts tended to decrease in everyone; however, the CD4% did not change.
• High rates of side effects were seen in the Victrelis group, including bad taste (28%), vomiting (28%), diarrhea (28%), anemia (41%), fever (36%), headache (23%), appetite loss (34%) and fatigue (36%). Serious anemia occurred in 5% and low neutrophil counts (27%).

A larger study will start enrolling by the end of the year.

For other coverage on this topic:
AIDSmeds.com
HIVandHepatitis
AIDSmap.com